Adjuvants in the driver's seat: How magnitude, type, fine specificity and longevity of immune responses are driven by distinct classes of immune potentiators

Vaccines

Volumn 2, Issue 2, 2014, Pages 252-296

  Bergmann Leitner, Elke S ^a   Leitner, Wolfgang W ^b  

^a US Military Malaria Vaccine Program   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Adjuvant; Immune epitope; Immune mechanism; Infectious disease; Mucosal immunity; Th1; Th17; Th2; Vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIGEN; BUFFER; CHEMOKINE; CYTOKINE; IMMUNOLOGICAL ADJUVANT; INFLAMMASOME; LIPOPOLYSACCHARIDE; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; VACCINE;

ANTIGEN PRESENTING CELL; ATTENUATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; INFLAMMATION; MACROPHAGE; MAST CELL; NATURAL KILLER T CELL; PARTICLE SIZE; PH; POLARIZATION; REVIEW; TH1 CELL; TH2 CELL; VACCINATION;

EID: 85019427467     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines2020252     Document Type: Review

References (225)

1. Hilleman, M.R. Vaccines in historic evolution and perspective: A narrative of vaccine discoveries. Vaccine 2000, 18, 1436-1447
2. Dormitzer, P.R.; Tsai, T.F.; del Giudice, G. New technologies for influenza vaccines. Hum. Vaccines Immunother. 2012, 8, 45-58
3. Nussenzweig, R.S.; Vanderberg, J.; Most, H.; Orton, C. Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei. Nature 1967, 216, 160-162
4. Wijayalath, W.; Cheesman, S.; Tanabe, K.; Handunnetti, S.; Carter, R.; Pathirana, S. Strain-specific protective effect of the immunity induced by live malarial sporozoites under chloroquine cover. PLoS One 2012, 7, e45861
5. Schwartz, J.L. The first rotavirus vaccine and the politics of acceptable risk. Milbank Q. 2012, 90, 278-310
6. Alving, C.R.; Peachman, K.K.; Rao, M.; Reed, S.G. Adjuvants for human vaccines. Curr. Opin. Immunol. 2012, 24, 310-315
7. Mbow, M.L.; de Gregorio, E.; Valiante, N.M.; Rappuoli, R. New adjuvants for human vaccines. Curr. Opin. Immunol. 2010, 22, 411-416
8. Gebril, A.; Alsaadi, M.; Acevedo, R.; Mullen, A.B.; Ferro, V.A. Optimizing efficacy of mucosal vaccines. Expert Rev. Vaccines 2012, 11, 1139-1155
9. Kobiyama, K.; Jounai, N.; Aoshi, T.; Tozuka, M.; Takeshita, F.; Coban, C.; Ishii, K.J. Innate Immune Signaling by, and Genetic Adjuvants for DNA Vaccination. Vaccines 2013, 1, 278-292
10. Baz, M.; Samant, M.; Zekki, H.; Tribout-Jover, P.; Plante, M.; Lanteigne, A.M.; Hamelin, M.E.; Mallett, C.; Papadopoulou, B.; Boivin, G. Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice. Clin. Vaccine Immunol. 2012, 19, 209-218
11. Tetsutani, K.; Ishii, K.J. Adjuvants in influenza vaccines. Vaccine 2012, 30, 7658-7661
12. Bergmann-Leitner, E.S.; Leitner, W.W.; Tsokos, G.C. Complement 3d: From molecular adjuvant to target of immune escape mechanisms. Clin. Immunol. 2006, 121, 177-185
13. Matzinger, P. Tolerance, Danger, and the Extended Family. Annu. Rev. Immunol. 1994, 12, 991-1045
14. Pizza, M.; Giuliani, M.M.; Fontana, M.R.; Monaci, E.; Douce, G.; Dougan, G.; Mills, K.H.G.; Rappuoli, R.; del Giudice, G. Mucosal vaccines: Non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 2001, 19, 2534-2541
15. Immunization Action Coalition. Available online: http://www.immunize.org/timeline (accessed on 20 March 2014).
16. Chen, J.; Pompano, R.R.; Santiago, F.W.; Maillat, L.; Sciammas, R.; Sun, T.; Han, H.; Topham, D.J.; Chong, A.S.; Collier, J.H. The use of self-adjuvanting nanofiber vaccines to elicit high-affinity B cell responses to peptide antigens without inflammation. Biomaterials 2013, 34, 8776-8785
17. Saade, F.; Honda-Okubo, Y.; Trec, S.; Petrovsky, N. A novel hepatitis B vaccine containing Advax, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing. Vaccine 2013, 31, 1999-2007
18. Wong, P.T.; Wang, S.H.; Ciotti, S.; Makidon, P.E.; Smith, D.M.; Fan, Y.; Schuler, C.F.; Baker, J.R. Formulation and Characterization of Nanoemulsion Intranasal Adjuvants: Effects of Surfactant Composition on Mucoadhesion and Immunogenicity. Mol. Pharm. 2014, 11, 531-544
19. Belz, G.T.; Carbone, F.R.; Heath, W.R. Cross-presentation of antigens by dendritic cells. Crit. Rev. Immunol. 2002, 22, 439-448
20. Murphy, B.R.; Coelingh, K. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol. 2002, 15, 295-323
21. Palm, N.W.; Medzhitov, R. Pattern recognition receptors and control of adaptive immunity. Immunol. Rev. 2009, 227, 221-233
22. Fernandez-Lizarbe, S.; Montesinos, J.; Guerri, C. Ethanol induces TLR4/TLR2 association, triggering an inflammatory response in microglial cells. J. Neurochem. 2013, 126, 261-273
23. Flach, T.L.; Ng, G.; Hari, A.; Desrosiers, M.D.; Zhang, P.; Ward, S.M.; Seamone, M.E.; Vilaysane, A.; Mucsi, A.D.; Fong, Y.; et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat. Med. 2011, 17, 479-487
24. Brito, L.A.; Malyala, P.; O'Hagan, D.T. Vaccine adjuvant formulations: A pharmaceutical perspective. Semin. Immunol. 2013, 25, 130-145
25. Pearse, M.J.; Drane, D. ISCOMATRIX adjuvant for antigen delivery. Adv. Drug Deliv. Rev. 2005, 57, 465-474
26. Tonkin, D.R.; Jorquera, P.; Todd, T.; Beard, C.W.; Johnston, R.E.; Barro, M. Alphavirus replicon-based enhancement of mucosal and systemic immunity is linked to the innate response generated by primary immunization. Vaccine 2010, 28, 3238-3246
27. Klinman, D.M. Adjuvant activity of CpG oligodeoxynucleotides. Int. Rev. Immunol. 2006, 25, 135-154
28. Glenny, A.T.; Pope, C.G.; Waddington, H.; Wallace, U. Immunological notes XVII-XXIV. J. Pathol. Bacteriol. 1926, 29, 31-40
29. Shi, Y.; HogenEsch, H.; Regnier, F.E.; Hem, S.L. Detoxification of endotoxin by aluminum hydroxide adjuvant. Vaccine 2001, 19, 1747-1752
30. Aebig, J.A.; Mullen, G.E.; Dobrescu, G.; Rausch, K.; Lambert, L.; Ajose-Popoola, O.; Long, C.A.; Saul, A.; Miles, A.P. Formulation of vaccines containing CpG oligonucleotides and alum. J. Immunol. Methods 2007, 323, 139-146
31. Cain, D.W.; Sanders, S.E.; Cunningham, M.M.; Kelsoe, G. Disparate adjuvant properties among three formulations of "alum". Vaccine 2013, 31, 653-660
32. Langemann, T.; Koller, V.J.; Muhammad, A.; Kudela, P.; Mayr, U.B.; Lubitz, W. The Bacterial Ghost platform system: Production and applications. Bioeng. Bugs 2010, 1, 326-336
33. Chan, M.; Hayashi, T.; Mathewson, R.D.; Yao, S.; Gray, C.; Tawatao, R.I.; Kalenian, K.; Zhang, Y.; Hayashi, Y.; Lao, F.S.; et al. Synthesis and characterization of PEGylated toll like receptor 7 ligands. Bioconjug. Chem. 2011, 22, 445-454
34. Makidon, P.E.; Belyakov, I.M.; Blanco, L.P.; Janczak, K.W.; Landers, J.; Bielinska, A.U.; Groom, J.V., 2nd; Baker, J.R., Jr. Nanoemulsion mucosal adjuvant uniquely activates cytokine production by nasal ciliated epithelium and induces dendritic cell trafficking. Eur. J. Immunol. 2012, 42, 2073-2086
35. Ott, G.; Barchfeld, G.L.; Chernoff, D.; Radhakrishnan, R.; van Hoogevest, P.; van Nest, G. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm. Biotechnol. 1995, 6, 277-296
36. Calabro, S.; Tritto, E.; Pezzotti, A.; Taccone, M.; Muzzi, A.; Bertholet, S.; de Gregorio, E.; O'Hagan, D.T.; Baudner, B.; Seubert, A. The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. Vaccine 2013, 31, 3363-3369
37. Stewart-Tull, D.E. The Use of Adjuvants in Experimental Vaccines: IV. ISCOMS. Methods Mol. Med. 1996, 4, 153-155
38. Sun, H.X.; Xie, Y.; Ye, Y.P. ISCOMs and ISCOMATRIX. Vaccine 2009, 27, 4388-4401
39. Gil, D.; Bracho, G.; Zayas, C.; del Campo, J.; Acevedo, R.; Toledo, A.; Lastre, M.; Perez, O. Strategy for determination of an efficient Cochleate particle size. Vaccine 2006, 24, S92-S93
40. Thomas, C.; Gupta, V.; Ahsan, F. Particle size influences the immune response produced by hepatitis B vaccine formulated in inhalable particles. Pharm. Res. 2010, 27, 905-919
41. Mastelic, B.; Garcon, N.; del Giudice, G.; Golding, H.; Gruber, M.; Neels, P.; Fritzell, B. Predictive markers of safety and immunogenicity of adjuvanted vaccines. Biologicals 2013, 41, 458-468
42. Cohen, J.A.; Beaudette, T.T.; Tseng, W.W.; Bachelder, E.M.; Mende, I.; Engleman, E.G.; Frechet, J.M. T-cell activation by antigen-loaded pH-sensitive hydrogel particles in vivo: The effect of particle size. Bioconjug. Chem. 2009, 20, 111-119
43. Yan, W.; Huang, L. The effects of salt on the physicochemical properties and immunogenicity of protein based vaccine formulated in cationic liposome. Int. J. Pharm. 2009, 368, 56-62
44. Abdel-Aal, A.B.; Zaman, M.; Fujita, Y.; Batzloff, M.R.; Good, M.F.; Toth, I. Design of three-component vaccines against group A streptococcal infections: Importance of spatial arrangement of vaccine components. J. Med. Chem. 2010, 53, 8041-8046
45. Mancini, R.J.; Tom, J.K.; Esser-Kahn, A.P. Covalently coupled immunostimulant heterodimers. Angew. Chem. Int. Ed. Engl. 2014, 53, 189-192
46. Liu, X.; Xu, Y.; Yu, T.; Clifford, C.; Liu, Y.; Yan, H.; Chang, Y. A DNA nanostructure platform for directed assembly of synthetic vaccines. Nano Lett. 2012, 12, 4254-4259
47. Ubol, S.; Halstead, S.B. How Innate Immune Mechanisms Contribute to Antibody-Enhanced Viral Infections. Clin. Vaccine Immunol. 2010, 17, 1829-1835
48. Delgado, M.F.; Coviello, S.; Monsalvo, A.C.; Melendi, G.A.; Hernandez, J.Z.; Batalle, J.P.; Diaz, L.; Trento, A.; Chang, H.Y.; Mitzner, W.; et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med. 2009, 15, 34-41
49. Hancock, G.E.; Heers, K.M.; Pryharski, K.S.; Smith, J.D.; Tiberio, L. Adjuvants recognized by toll-like receptors inhibit the induction of polarized type 2 T cell responses by natural attachment (G) protein of respiratory syncytial virus. Vaccine 2003, 21, 4348-4358
50. Amanna, I.J.; Raue, H.P.; Slifka, M.K. Development of a new hydrogen peroxide-based vaccine platform. Nat. Med. 2012, 18, 974-979
51. Casella, C.R.; Mitchell, T.C. Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell. Mol. Life Sci. 2008, 65, 3231-3240
52. Cekic, C.; Casella, C.R.; Eaves, C.A.; Matsuzawa, A.; Ichijo, H.; Mitchell, T.C. Selective activation of the p38 MAPK pathway by synthetic monophosphoryl lipid A. J. Biol. Chem. 2009, 284, 31982-31991
53. Caproni, E.; Tritto, E.; Cortese, M.; Muzzi, A.; Mosca, F.; Monaci, E.; Baudner, B.; Seubert, A.; de Gregorio, E. MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I-independent mechanism of action. J. Immunol. 2012, 188, 3088-3098
54. Bowen, W.S.; Minns, L.A.; Johnson, D.A.; Mitchell, T.C.; Hutton, M.M.; Evans, J.T. Selective TRIF-dependent signaling by a synthetic toll-like receptor 4 agonist. Sci. Signal. 2012, 5, doi:10.1126/scisignal.2001963
55. Thompson, B.S.; Chilton, P.M.; Ward, J.R.; Evans, J.T.; Mitchell, T.C. The low-toxicity versions of LPS, MPL adjuvant and RC529, are efficient adjuvants for CD4+ T cells. J. Leukoc. Biol. 2005, 78, 1273-1280
56. Shukla, N.M.; Lewis, T.C.; Day, T.P.; Mutz, C.A.; Ukani, R.; Hamilton, C.D.; Balakrishna, R.; David, S.A. Toward self-adjuvanting subunit vaccines: Model peptide and protein antigens incorporating covalently bound toll-like receptor-7 agonistic imidazoquinolines. Bioorg. Med. Chem. Lett. 2011, 21, 3232-3236
57. Oh, J.Z.; Kedl, R.M. The capacity to induce cross-presentation dictates the success of a TLR7 agonist-conjugate vaccine for eliciting cellular immunity. J. Immunol. 2010, 185, 4602-4608
58. Feng, Y.; Forsell, M.N.; Flynn, B.; Adams, W.; Lore, K.; Seder, R.; Wyatt, R.T.; Karlsson Hedestam, G.B. Chemical cross-linking of HIV-1 Env for direct TLR7/8 ligand conjugation compromises recognition of conserved antigenic determinants. Virology 2013, 446, 56-65
59. Fischer, N.O.; Rasley, A.; Corzett, M.; Hwang, M.H.; Hoeprich, P.D.; Blanchette, C.D. Colocalized delivery of adjuvant and antigen using nanolipoprotein particles enhances the immune response to recombinant antigens. J. Am. Chem. Soc. 2013, 135, 2044-2047
60. Khurana, S.; Chearwae, W.; Castellino, F.; Manischewitz, J.; King, L.R.; Honorkiewicz, A.; Rock, M.T.; Edwards, K.M.; del Giudice, G.; Rappuoli, R.; et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci. Transl. Med. 2010, 2, doi:10.1126/scitranslmed.3000624
61. Shukla, N.M.; Salunke, D.B.; Balakrishna, R.; Mutz, C.A.; Malladi, S.S.; David, S.A. Potent adjuvanticity of a pure TLR7-agonistic imidazoquinoline dendrimer. PLoS One 2012, 7, e43612
62. Guiducci, C.; Gong, M.; Cepika, A.M.; Xu, Z.; Tripodo, C.; Bennett, L.; Crain, C.; Quartier, P.; Cush, J.J.; Pascual, V.; et al. RNA recognition by human TLR8 can lead to autoimmune inflammation. J. Exp. Med. 2013, 210, 2903-2919
63. Saenz, R.; Souza Cda, S.; Huang, C.T.; Larsson, M.; Esener, S.; Messmer, D. HMGB1-derived peptide acts as adjuvant inducing immune responses to peptide and protein antigen. Vaccine 2010, 28, 7556-7562
64. Martinez-Gil, L.; Ayllon, J.; Ortigoza, M.B.; Garcia-Sastre, A.; Shaw, M.L.; Palese, P. Identification of small molecules with type I interferon inducing properties by high-throughput screening. PLoS One 2012, 7, e49049
65. Chan, M.; Hayashi, T.; Mathewson, R.D.; Nour, A.; Hayashi, Y.; Yao, S.; Tawatao, R.I.; Crain, B.; Tsigelny, I.F.; Kouznetsova, V.L.; et al. Identification of substituted pyrimido[5,4-b]indoles as selective Toll-like receptor 4 ligands. J. Med. Chem. 2013, 56, 4206-4223
66. Pashine, A.; Valiante, N.M.; Ulmer, J.B. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 2005, 11, S63-S68
67. Fritz, J.H.; Le Bourhis, L.; Magalhaes, J.G.; Philpott, D.J. Innate immune recognition at the epithelial barrier drives adaptive immunity: APCs take the back seat. Trends Immunol. 2008, 29, 41-49
68. Bobanga, I.D.; Petrrosiute, A.; Huang, A.Y. Chemokines as Cancer Vaccine Adjuvants. Vaccines 2013, 1, 444-462
69. Awate, S.; Babiuk, L.A.; Mutwiri, G. Mechanisms of action of adjuvants. Front. Immunol. 2013, 4, doi:10.3389/fimmu.2013.00114
70. Abebe, F. Is interferon-gamma the right marker for bacille Calmette-Guerin-induced immune protection? The missing link in our understanding of tuberculosis immunology. Clin. Exp. Immunol. 2012, 169, 213-219
71. Zaitseva, M.; Romantseva, T.; Blinova, K.; Beren, J.; Sirota, L.; Drane, D.; Golding, H. Use of human MonoMac6 cells for development of in vitro assay predictive of adjuvant safety in vivo. Vaccine 2012, 30, 4859-4865
72. Calabro, S.; Tortoli, M.; Baudner, B.C.; Pacitto, A.; Cortese, M.; O'Hagan, D.T.; de Gregorio, E.; Seubert, A.; Wack, A. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 2011, 29, 1812-1823
73. Lambert, S.L.; Yang, C.F.; Liu, Z.; Sweetwood, R.; Zhao, J.; Cheng, L.L.; Jin, H.; Woo, J. Molecular and Cellular Response Profiles Induced by the TLR4 Agonist-Based Adjuvant Glucopyranosyl Lipid A. PLoS One 2012, 7, e51618
74. Yang, C.W.; Strong, B.S.; Miller, M.J.; Unanue, E.R. Neutrophils influence the level of antigen presentation during the immune response to protein antigens in adjuvants. J. Immunol. 2010, 185, 2927-2934
75. Lambrecht, B.N.; Kool, M.; Willart, M.A.; Hammad, H. Mechanism of action of clinically approved adjuvants. Curr. Opin. Immunol. 2009, 21, 23-29
76. Baumgartner, C.K.; Malherbe, L.P. Regulation of CD4 T-cell receptor diversity by vaccine adjuvants. Immunology 2010, 130, 16-22
77. Lynch, H.E.; Stewart, S.M.; Kepler, T.B.; Sempowski, G.D.; Alam, S.M. Surface plasmon resonance measurements of plasma antibody avidity during primary and secondary responses to anthrax protective antigen. J. Immunol. Methods 2014, 404, 1-12
78. Vajdy, M.; Lycke, N.Y. Cholera toxin adjuvant promotes long-term immunological memory in the gut mucosa to unrelated immunogens after oral immunization. Immunology 1992, 75, 488-492
79. Leitner, W.W. Vaccine adjuvants: Is the pipeline clogged? Immunotherapy 2012, 4, 565-567
80. Khong, H.T.; Yang, J.C.; Topalian, S.L.; Sherry, R.M.; Mavroukakis, S.A.; White, D.E.; Rosenberg, S.A. Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J. Immunother. 2004, 27, 472-477
81. Brinckerhoff, L.H.; Kalashnikov, V.V.; Thompson, L.W.; Yamshchikov, G.V.; Pierce, R.A.; Galavotti, H.S.; Engelhard, V.H.; Slingluff, C.L., Jr. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: Implications for peptide vaccines. Int. J. Cancer. 1999, 83, 326-334
82. Querec, T.; Bennouna, S.; Alkan, S.; Laouar, Y.; Gorden, K.; Flavell, R.; Akira, S.; Ahmed, R.; Pulendran, B. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 2006, 203, 413-424
83. Higgins, S.C.; Mills, K.H. TLR, NLR Agonists, and Other Immune Modulators as Infectious Disease Vaccine Adjuvants. Curr. Infect. Dis. Rep. 2010, 12, 4-12
84. Kobayashi, H.; Horner, A.A.; Takabayashi, K.; Nguyen, M.D.; Huang, E.; Cinman, N.; Raz, E. Immunostimulatory DNA pre-priming: A novel approach for prolonged Th1-biased immunity. Cell. Immunol. 1999, 198, 69-75
85. Krieg, A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 2002, 20, 709-760
86. Lipford, G.B.; Sparwasser, T.; Bauer, M.; Zimmermann, S.; Koch, E.S.; Heeg, K.; Wagner, H. Immunostimulatory DNA: Sequence-dependent production of potentially harmful or useful cytokines. Eur. J. Immunol. 1997, 27, 3420-3426
87. Mizel, S.B.; Bates, J.T. Flagellin as an adjuvant: Cellular mechanisms and potential. J. Immunol. 2010, 185, 5677-5682
88. Turley, C.B.; Rupp, R.E.; Johnson, C.; Taylor, D.N.; Wolfson, J.; Tussey, L.; Kavita, U.; Stanberry, L.; Shaw, A. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 2011, 29, 5145-5152
89. Nguyen, C.T.; Hong, S.H.; Sin, J.I.; Vu, H.V.; Jeong, K.; Cho, K.O.; Uematsu, S.; Akira, S.; Lee, S.E.; Rhee, J.H. Flagellin enhances tumor-specific CD8(+) T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model. Vaccine 2013, 31, 3879-3887
90. Braga, C.J.; Massis, L.M.; Sbrogio-Almeida, M.E.; Alencar, B.C.; Bargieri, D.Y.; Boscardin, S.B.; Rodrigues, M.M.; Ferreira, L.C. CD8+ T cell adjuvant effects of Salmonella FliCd flagellin in live vaccine vectors or as purified protein. Vaccine 2010, 28, 1373-1382
91. Meyer, T.; Surber, C.; French, L.E.; Stockfleth, E. Resiquimod, a topical drug for viral skin lesions and skin cancer. Expert Opin. Investig. Drugs 2013, 22, 149-159
92. Steinhagen, F.; Kinjo, T.; Bode, C.; Klinman, D.M. TLR-based immune adjuvants. Vaccine 2011, 29, 3341-3355
93. Dzopalic, T.; Dragicevic, A.; Vasilijic, S.; Vucevic, D.; Majstorovic, I.; Bozic, B.; Balint, B.; Colic, M. Loxoribine, a selective Toll-like receptor 7 agonist, induces maturation of human monocyte-derived dendritic cells and stimulates their Th-1- and Th-17-polarizing capability. Int. Immunopharmacol. 2010, 10, 1428-1433
94. Crespo, M.I.; Zacca, E.R.; Nunez, N.G.; Ranocchia, R.P.; Maccioni, M.; Maletto, B.A.; Pistoresi-Palencia, M.C.; Moron, G. TLR7 triggering with polyuridylic acid promotes cross-presentation in CD8alpha+ conventional dendritic cells by enhancing antigen preservation and MHC class I antigen permanence on the dendritic cell surface. J. Immunol. 2013, 190, 948-960
95. Ngoi, S.M.; Tovey, M.G.; Vella, A.T. Targeting poly(I:C) to the TLR3-independent pathway boosts effector CD8 T cell differentiation through IFN-alpha/beta. J. Immunol. 2008, 181, 7670-7680
96. Wick, D.A.; Martin, S.D.; Nelson, B.H.; Webb, J.R. Profound CD8+ T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C). Vaccine 2011, 29, 984-993
97. Okada, H.; Kalinski, P.; Ueda, R.; Hoji, A.; Kohanbash, G.; Donegan, T.E.; Mintz, A.H.; Engh, J.A.; Bartlett, D.L.; Brown, C.K.; et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J. Clin. Oncol. 2011, 29, 330-336
98. Sabbatini, P.; Tsuji, T.; Ferran, L.; Ritter, E.; Sedrak, C.; Tuballes, K.; Jungbluth, A.A.; Ritter, G.; Aghajanian, C.; Bell-McGuinn, K.; et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin. Cancer Res. 2012, 18, 6497-6508
99. Quinn, K.M.; Yamamoto, A.; Costa, A.; Darrah, P.A.; Lindsay, R.W.; Hegde, S.T.; Johnson, T.R.; Flynn, B.J.; Lore, K.; Seder, R.A. Coadministration of Polyinosinic:Polycytidylic Acid and Immunostimulatory Complexes Modifies Antigen Processing in Dendritic Cell Subsets and Enhances HIV Gag-Specific T Cell Immunity. J. Immunol. 2013, 191, 5085-5096
100. Sanders, M.T.; Brown, L.E.; Deliyannis, G.; Pearse, M.J. ISCOM-based vaccines: The second decade. Immunol. Cell Biol. 2005, 83, 119-128
101. Polakos, N.K.; Drane, D.; Cox, J.; Ng, P.; Selby, M.J.; Chien, D.; O'Hagan, D.T.; Houghton, M.; Paliard, X. Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine. J. Immunol. 2001, 166, 3589-3598
102. Arias, M.A.; van Roey, G.A.; Tregoning, J.S.; Moutaftsi, M.; Coler, R.N.; Windish, H.P.; Reed, S.G.; Carter, D.; Shattock, R.J. Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140. PLoS One 2012, 7, e41144
103. Hayashi, E.A.; Granato, A.; Paiva, L.S.; Bertho, A.L.; Bellio, M.; Nobrega, A. TLR4 promotes B cell maturation: Independence and cooperation with B lymphocyte-activating factor. J. Immunol. 2010, 184, 4662-4672
104. Hwang, I.Y.; Park, C.; Harrison, K.; Kehrl, J.H. TLR4 signaling augments B lymphocyte migration and overcomes the restriction that limits access to germinal center dark zones. J. Exp. Med. 2009, 206, 2641-2657
105. O'Connor, B.P.; Vogel, L.A.; Zhang, W.; Loo, W.; Shnider, D.; Lind, E.F.; Ratliff, M.; Noelle, R.J.; Erickson, L.D. Imprinting the fate of antigen-reactive B cells through the affinity of the B cell receptor. J. Immunol. 2006, 177, 7723-7732
106. John, B.; Crispe, I.N. TLR-4 regulates CD8+ T cell trapping in the liver. J. Immunol. 2005, 175, 1643-1650
107. Crispe, I.N. The liver as a lymphoid organ. Annu. Rev. Immunol. 2009, 27, 147-163
108. Khodai, T.; Chappell, D.; Christy, C.; Cockle, P.; Eyles, J.; Hammond, D.; Gore, K.; McCluskie, M.J.; Evans, D.M.; Lang, S.; et al. Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models. Clin. Vaccine Immunol. 2011, 18, 1702-1709
109. Aachoui, Y.; Chowdhury, R.R.; Fitch, R.W.; Ghosh, S.K. Molecular signatures of phytol-derived immunostimulants in the context of chemokine-cytokine microenvironment and enhanced immune response. Cell. Immunol. 2011, 271, 227-238
110. Aachoui, Y.; Schulte, M.L.; Fitch, R.W.; Ghosh, S.K. Synthetic adjuvants for vaccine formulations: Evaluation of new phytol derivatives in induction and persistence of specific immune response. Cell. Immunol. 2011, 271, 308-318
111. Lim, S.Y.; Meyer, M.; Kjonaas, R.A.; Ghosh, S.K. Phytol-based novel adjuvants in vaccine formulation: 1. assessment of safety and efficacy during stimulation of humoral and cell-mediated immune responses. J. Immune Based Ther. Vaccines 2006, 4, doi:10.1186/1476-8518-4-6
112. Bouvier, I.; Jusforgues-Saklani, H.; Lim, A.; Lemaitre, F.; Lemercier, B.; Auriau, C.; Nicola, M.A.; Leroy, S.; Law, H.K.; Bandeira, A.; et al. Immunization route dictates cross-priming efficiency and impacts the optimal timing of adjuvant delivery. Front. Immunol. 2011, 2, doi:10.3389/fimmu.2011.00071
113. Li, H.; Li, Y.; Jiao, J.; Hu, H.M. Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response. Nat. Nanotechnol. 2011, 6, 645-650
114. Scott, E.A.; Stano, A.; Gillard, M.; Maio-Liu, A.C.; Swartz, M.A.; Hubbell, J.A. Dendritic cell activation and T cell priming with adjuvant- and antigen-loaded oxidation-sensitive polymersomes. Biomaterials 2012, 33, 6211-6219
115. Xiang, S.D.; Wilson, K.; Day, S.; Fuchsberger, M.; Plebanski, M. Methods of effective conjugation of antigens to nanoparticles as non-inflammatory vaccine carriers. Methods 2013, 60, 232-241
116. Duewell, P.; Kisser, U.; Heckelsmiller, K.; Hoves, S.; Stoitzner, P.; Koernig, S.; Morelli, A.B.; Clausen, B.E.; Dauer, M.; Eigler, A.; et al. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells. J. Immunol. 2011, 187, 55-63
117. Wilson, N.S.; Yang, B.; Morelli, A.B.; Koernig, S.; Yang, A.; Loeser, S.; Airey, D.; Provan, L.; Hass, P.; Braley, H.; et al. ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway. Immunol. Cell. Biol. 2012, 90, 540-552
118. Kastenmuller, K.; Wille-Reece, U.; Lindsay, R.W.; Trager, L.R.; Darrah, P.A.; Flynn, B.J.; Becker, M.R.; Udey, M.C.; Clausen, B.E.; Igyarto, B.Z.; et al. Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. J. Clin. Investig. 2011, 121, 1782-1796
119. Jelinek, I.; Leonard, J.N.; Price, G.E.; Brown, K.N.; Meyer-Manlapat, A.; Goldsmith, P.K.; Wang, Y.; Venzon, D.; Epstein, S.L.; Segal, D.M. TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection. J. Immunol. 2011, 186, 2422-2429
120. Coffman, R.L.; Sher, A.; Seder, R.A. Vaccine adjuvants: Putting innate immunity to work. Immunity 2010, 33, 492-503
121. Longhi, M.P.; Trumpfheller, C.; Idoyaga, J.; Caskey, M.; Matos, I.; Kluger, C.; Salazar, A.M.; Colonna, M.; Steinman, R.M. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J. Exp. Med. 2009, 206, 1589-1602
122. Wilson, N.S.; Behrens, G.M.; Lundie, R.J.; Smith, C.M.; Waithman, J.; Young, L.; Forehan, S.P.; Mount, A.; Steptoe, R.J.; Shortman, K.D.; et al. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat. Immunol. 2006, 7, 165-172
123. Rhee, E.G.; Kelley, R.P.; Agarwal, I.; Lynch, D.M.; La Porte, A.; Simmons, N.L.; Clark, S.L.; Barouch, D.H. TLR4 ligands augment antigen-specific CD8+ T lymphocyte responses elicited by a viral vaccine vector. J. Virol. 2010, 84, 10413-10419
124. Appledorn, D.M.; Aldhamen, Y.A.; Depas, W.; Seregin, S.S.; Liu, C.J.; Schuldt, N.; Quach, D.; Quiroga, D.; Godbehere, S.; Zlatkin, I.; et al. A new adenovirus based vaccine vector expressing an Eimeria tenella derived TLR agonist improves cellular immune responses to an antigenic target. PLoS One 2010, 5, e9579
125. Hailemichael, Y.; Overwijk, W.W. Peptide-based anticancer vaccines: The making and unmaking of a T-cell graveyard. Oncoimmunology 2013, 2, e24743
126. Salerno, E.P.; Shea, S.M.; Olson, W.C.; Petroni, G.R.; Smolkin, M.E.; McSkimming, C.; Chianese-Bullock, K.A.; Slingluff, C.L., Jr. Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide. Cancer Immunol. Immunother. 2013, 62, 1149-1159
127. Song, X.T.; Evel-Kabler, K.; Rollins, L.; Aldrich, M.; Gao, F.; Huang, X.F.; Chen, S.Y. An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. PLoS Med. 2006, 3, e11
128. Seubert, A.; Calabro, S.; Santini, L.; Galli, B.; Genovese, A.; Valentini, S.; Aprea, S.; Colaprico, A.; D'Oro, U.; Giuliani, M.M.; et al. Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc. Natl. Acad. Sci. USA 2011, 108, 11169-11174
129. Shenderov, K.; Barber, D.L.; Mayer-Barber, K.D.; Gurcha, S.S.; Jankovic, D.; Feng, C.G.; Oland, S.; Hieny, S.; Caspar, P.; Yamasaki, S.; et al. Cord factor and peptidoglycan recapitulate the Th17-promoting adjuvant activity of mycobacteria through mincle/CARD9 signaling and the inflammasome. J. Immunol. 2013, 190, 5722-5730
130. Gandhapudi, S.K.; Chilton, P.M.; Mitchell, T.C. TRIF is required for TLR4 mediated adjuvant effects on T cell clonal expansion. PLoS One 2013, 8, e56855
131. Mata-Haro, V.; Cekic, C.; Martin, M.; Chilton, P.M.; Casella, C.R.; Mitchell, T.C. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007, 316, 1628-1632
132. Hagar, J.A.; Powell, D.A.; Aachoui, Y.; Ernst, R.K.; Miao, E.A. Cytoplasmic LPS activates caspase-11: Implications in TLR4-independent endotoxic shock. Science 2013, 341, 1250-1253
133. Kool, M.; Fierens, K.; Lambrecht, B.N. Alum adjuvant: Some of the tricks of the oldest adjuvant. J. Med. Microbiol. 2012, 61, 927-934
134. Marrack, P.; McKee, A.S.; Munks, M.W. Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 2009, 9, 287-293
135. Hutchison, S.; Benson, R.A.; Gibson, V.B.; Pollock, A.H.; Garside, P.; Brewer, J.M. Antigen depot is not required for alum adjuvanticity. FASEB J. 2012, 26, 1272-1279
136. Zuidscherwoude, M.; de Winde, C.M.; Cambi, A.; van Spriel, A.B. Microdomains in the membrane landscape shape antigen-presenting cell function. J. Leukoc. Biol. 2014, 95, 251-263
137. Eisenbarth, S.C.; Colegio, O.R.; O'Connor, W.; Sutterwala, F.S.; Flavell, R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008, 453, 1122-1126
138. Li, H.; Willingham, S.B.; Ting, J.P.; Re, F. Cutting edge: Inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J. Immunol. 2008, 181, 17-21
139. Kool, M.; Petrilli, V.; de Smedt, T.; Rolaz, A.; Hammad, H.; van Nimwegen, M.; Bergen, I.M.; Castillo, R.; Lambrecht, B.N.; Tschopp, J. Cutting edge: Alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J. Immunol. 2008, 181, 3755-3759
140. Vaine, C.A.; Patel, M.K.; Zhu, J.; Lee, E.; Finberg, R.W.; Hayward, R.C.; Kurt-Jones, E.A. Tuning innate immune activation by surface texturing of polymer microparticles: The role of shape in inflammasome activation. J. Immunol. 2013, 190, 3525-3532
141. Liu, Y.; Tian, X.; Leitner, W.W.; Aldridge, M.E.; Zheng, J.; Yu, Z.; Restifo, N.P.; Weiss, R.; Scheiblhofer, S.; Xie, C.; et al. Polymeric structure and host Toll-like receptor 4 dictate immunogenicity of NY-ESO-1 antigen in vivo. J. Biol. Chem. 2011, 286, 37077-37084
142. Timmermans, K.; Plantinga, T.S.; Kox, M.; Vaneker, M.; Scheffer, G.J.; Adema, G.J.; Joosten, L.A.; Netea, M.G. Blueprints of signaling interactions between pattern recognition receptors: Implications for the design of vaccine adjuvants. Clin. Vaccine Immunol. 2013, 20, 427-432
143. Van den Berg, J.H.; Quaak, S.G.; Beijnen, J.H.; Hennink, W.E.; Storm, G.; Schumacher, T.N.; Haanen, J.B.; Nuijen, B. Lipopolysaccharide contamination in intradermal DNA vaccination: Toxic impurity or adjuvant? Int. J. Pharm. 2010, 390, 32-36
144. Kool, M.; Soullie, T.; van Nimwegen, M.; Willart, M.A.; Muskens, F.; Jung, S.; Hoogsteden, H.C.; Hammad, H.; Lambrecht, B.N. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J. Exp. Med. 2008, 205, 869-882
145. Ferguson, T.A.; Choi, J.; Green, D.R. Armed response: How dying cells influence T-cell functions. Immunol. Rev. 2011, 241, 77-88
146. Moriwaki, K.; Chan, F.K. RIP3: A molecular switch for necrosis and inflammation. Genes Dev. 2013, 27, 1640-1649
147. Schon, M.P.; Wienrich, B.G.; Drewniok, C.; Bong, A.B.; Eberle, J.; Geilen, C.C.; Gollnick, H.; Schon, M. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J. Investig. Dermatol. 2004, 122, 1266-1276
148. Leitner, W.W.; Hwang, L.N.; Bergmann-Leitner, E.S.; Finkelstein, S.E.; Frank, S.; Restifo, N.P. Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines. Vaccine 2004, 22, 1537-1544
149. Bergmann-Leitner, E.S.; Leitner, W.W. Danger, death and DNA vaccines. Microbes Infect. 2004, 6, 319-327
150. Salaun, B.; Romero, P.; Lebecque, S. Toll-like receptors' two-edged sword: When immunity meets apoptosis. Eur. J. Immunol. 2007, 37, 3311-3318
151. Schon, M.; Bong, A.B.; Drewniok, C.; Herz, J.; Geilen, C.C.; Reifenberger, J.; Benninghoff, B.; Slade, H.B.; Gollnick, H.; Schon, M.P. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J. Natl. Cancer Inst. 2003, 95, 1138-1149
152. Wegmann, F.; Gartlan, K.H.; Harandi, A.M.; Brinckmann, S.A.; Coccia, M.; Hillson, W.R.; Kok, W.L.; Cole, S.; Ho, L.P.; Lambe, T.; et al. Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens. Nat. Biotechnol. 2012, 30, 883-888
153. Yang, Y.W.; Wu, C.A.; Morrow, W.J. The apoptotic and necrotic effects of tomatine adjuvant. Vaccine 2004, 22, 2316-2327
154. Marichal, T.; Ohata, K.; Bedoret, D.; Mesnil, C.; Sabatel, C.; Kobiyama, K.; Lekeux, P.; Coban, C.; Akira, S.; Ishii, K.J.; et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat. Med. 2011, 17, 996-1002
155. Hornung, V.; Bauernfeind, F.; Halle, A.; Samstad, E.O.; Kono, H.; Rock, K.L.; Fitzgerald, K.A.; Latz, E. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 2008, 9, 847-856
156. Droga-Mazovec, G.; Bojic, L.; Petelin, A.; Ivanova, S.; Romih, R.; Repnik, U.; Salvesen, G.S.; Stoka, V.; Turk, V.; Turk, B. Cysteine cathepsins trigger caspase-dependent cell death through cleavage of bid and antiapoptotic Bcl-2 homologues. J. Biol. Chem. 2008, 283, 19140-19150
157. Lima, H., Jr.; Jacobson, L.S.; Goldberg, M.F.; Chandran, K.; Diaz-Griffero, F.; Lisanti, M.P.; Brojatsch, J. Role of lysosome rupture in controlling Nlrp3 signaling and necrotic cell death. Cell Cycle 2013, 12, 1868-1878
158. Guicciardi, M.E.; Gores, G.J. Complete lysosomal disruption: A route to necrosis, not to the inflammasome. Cell Cycle 2013, 12, doi:10.4161/cc.25317
159. Kono, H.; Orlowski, G.M.; Patel, Z.; Rock, K.L. The IL-1-dependent sterile inflammatory response has a substantial caspase-1-independent component that requires cathepsin C. J. Immunol. 2012, 189, 3734-3740
160. Murakami, T.; Ockinger, J.; Yu, J.; Byles, V.; McColl, A.; Hofer, A.M.; Horng, T. Critical role for calcium mobilization in activation of the NLRP3 inflammasome. Proc. Natl. Acad. Sci. USA 2012, 109, 11282-11287
161. Seubert, A.; Monaci, E.; Pizza, M.; O'Hagan, D.T.; Wack, A. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J. Immunol. 2008, 180, 5402-5412
162. Vinuesa, C.G.; Chang, P.P. Innate B cell helpers reveal novel types of antibody responses. Nat. Immunol. 2013, 14, 119-126
163. Schmieg, J.; Yang, G.; Franck, R.W.; Tsuji, M. A multifactorial mechanism in the superior antimalarial activity of alpha-C-GalCer. J. Biomed. Biotechnol. 2010, doi:10.1155/2010/283612
164. Schmieg, J.; Gonzalez-Aseguinolaza, G.; Tsuji, M. The role of natural killer T cells and other T cell subsets against infection by the pre-erythrocytic stages of malaria parasites. Microbes Infect. 2003, 5, 499-506
165. Padte, N.N.; Li, X.; Tsuji, M.; Vasan, S. Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant. Clin. Immunol. 2011, 140, 142-151
166. Guillonneau, C.; Mintern, J.D.; Hubert, F.X.; Hurt, A.C.; Besra, G.S.; Porcelli, S.; Barr, I.G.; Doherty, P.C.; Godfrey, D.I.; Turner, S.J. Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity. Proc. Natl. Acad. Sci. USA 2009, 106, 3330-3335
167. Kamijuku, H.; Nagata, Y.; Jiang, X.; Ichinohe, T.; Tashiro, T.; Mori, K.; Taniguchi, M.; Hase, K.; Ohno, H.; Shimaoka, T.; et al. Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide, which can induce cross-protection against influenza viruses. Mucosal Immunol. 2008, 1, 208-218
168. Gonzalez-Aseguinolaza, G.; van Kaer, L.; Bergmann, C.C.; Wilson, J.M.; Schmieg, J.; Kronenberg, M.; Nakayama, T.; Taniguchi, M.; Koezuka, Y.; Tsuji, M. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J. Exp. Med. 2002, 195, 617-624
169. Devera, T.S.; Shah, H.B.; Lang, G.A.; Lang, M.L. Glycolipid-activated NKT cells support the induction of persistent plasma cell responses and antibody titers. Eur. J. Immunol. 2008, 38, 1001-1011
170. Bai, L.; Deng, S.; Reboulet, R.; Mathew, R.; Teyton, L.; Savage, P.B.; Bendelac, A. Natural killer T (NKT)-B-cell interactions promote prolonged antibody responses and long-term memory to pneumococcal capsular polysaccharides. Proc. Natl. Acad. Sci. USA 2013, 110, 16097-16102
171. Chang, D.H.; Osman, K.; Connolly, J.; Kukreja, A.; Krasovsky, J.; Pack, M.; Hutchinson, A.; Geller, M.; Liu, N.; Annable, R.; et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. 2005, 201, 1503-1517
172. McKee, A.S.; Munks, M.W.; MacLeod, M.K.; Fleenor, C.J.; van Rooijen, N.; Kappler, J.W.; Marrack, P. Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J. Immunol. 2009, 183, 4403-4414
173. Paton, W.D. Compound 48/80: A potent histamine liberator. Br. J. Pharmacol. Chemother. 1951, 6, 499-508
174. McLachlan, J.B.; Shelburne, C.P.; Hart, J.P.; Pizzo, S.V.; Goyal, R.; Brooking-Dixon, R.; Staats, H.F.; Abraham, S.N. Mast cell activators: A new class of highly effective vaccine adjuvants. Nat. Med. 2008, 14, 536-541
175. Esposito, S.; Montinaro, V.; Groppali, E.; Tenconi, R.; Semino, M.; Principi, N. Live attenuated intranasal influenza vaccine. Hum. Vaccin. Immunother. 2012, 8, 76-80
176. Harkema, J.R.; Carey, S.A.; Wagner, J.G. The nose revisited: A brief review of the comparative structure, function, and toxicologic pathology of the nasal epithelium. Toxicol. Pathol. 2006, 34, 252-269
177. Ichinohe, T.; Tamura, S.I.; Kawaguchi, A.; Ninomiya, A.; Imai, M.; Itamura, S.; Odagiri, T.; Tashiro, M.; Takahashi, H.; Sawa, H.; et al. Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J. Infect. Dis. 2007, 196, 1313-1320
178. Martinez-Gil, L.; Goff, P.H.; Hai, R.; Garcia-Sastre, A.; Shaw, M.L.; Palese, P. A Sendai virus-derived RNA agonist of RIG-I as a virus vaccine adjuvant. J. Virol. 2013, 87, 1290-1300
179. Mutsch, M.; Zhou, W.; Rhodes, P.; Bopp, M.; Chen, R.T.; Linder, T.; Spyr, C.; Steffen, R. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 2004, 350, 896-903
180. Fujihashi, K.; Koga, T.; van Ginkel, F.W.; Hagiwara, Y.; McGhee, J.R. A dilemma for mucosal vaccination: Efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 2002, 20, 2431-2438
181. Das, S.C.; Hatta, M.; Wilker, P.R.; Myc, A.; Hamouda, T.; Neumann, G.; Baker, J.R.; Kawaoka, Y. Nanoemulsion W(80)5EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine. Vaccine 2012, 30, 6871-6877
182. Bielinska, A.U.; Gerber, M.; Blanco, L.P.; Makidon, P.E.; Janczak, K.W.; Beer, M.; Swanson, B.; Baker, J.R., Jr. Induction of Th17 cellular immunity with a novel nanoemulsion adjuvant. Crit. Rev. Immunol. 2010, 30, 189-199
183. Miller, M.S.; Gardner, T.J.; Krammer, F.; Aguado, L.C.; Tortorella, D.; Basler, C.F.; Palese, P. Neutralizing antibodies against previously encountered influenza virus strains increase over time: A longitudinal analysis. Sci. Transl. Med. 2013, 5, doi:10.1126/scitranslmed.3006637
184. Ballou, W.R. The development of the RTS,S malaria vaccine candidate: Challenges and lessons. Parasite Immunol. 2009, 31, 492-500
185. Hutnick, N.A.; Myles, D.J.; Bian, C.B.; Muthumani, K.; Weiner, D.B. Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo. Curr. Opin. Virol. 2011, 1, 233-240
186. Lu, S. Heterologous prime-boost vaccination. Curr. Opin. Immunol. 2009, 21, 346-351
187. Leitner, W.W.; Seguin, M.C.; Ballou, W.R.; Seitz, J.P.; Schultz, A.M.; Sheehy, M.J.; Lyon, J.A. Immune responses induced by intramuscular or gene gun injection of protective deoxyribonucleic acid vaccines that express the circumsporozoite protein from Plasmodium berghei malaria parasites. J. Immunol. 1997, 159, 6112-6119
188. Kester, K.E.; Cummings, J.F.; Ockenhouse, C.F.; Nielsen, R.; Hall, B.T.; Gordon, D.M.; Schwenk, R.J.; Krzych, U.; Holland, C.A.; Richmond, G.; et al. Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine 2008, 26, 2191-2202
189. Stoute, J.A.; Slaoui, M.; Heppner, D.G.; Momin, P.; Kester, K.E.; Desmons, P.; Wellde, B.T.; Garcon, N.; Krzych, U.; Marchand, M. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N. Engl. J. Med. 1997, 336, 86-91
190. Sallusto, F.; Lanzavecchia, A.; Araki, K.; Ahmed, R. From vaccines to memory and back. Immunity 2010, 33, 451-463
191. Masopust, D.; Ha, S.J.; Vezys, V.; Ahmed, R. Stimulation history dictates memory CD8 T cell phenotype: Implications for prime-boost vaccination. J. Immunol. 2006, 177, 831-839
192. Leitner, W.W.; Hwang, L.N.; deVeer, M.J.; Zhou, A.; Silverman, R.H.; Williams, B.R.; Dubensky, T.W.; Ying, H.; Restifo, N.P. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat. Med. 2003, 9, 33-39
193. Hawkins, W.G.; Gold, J.S.; Blachere, N.E.; Bowne, W.B.; Hoos, A.; Lewis, J.J.; Houghton, A.N. Xenogeneic DNA immunization in melanoma models for minimal residual disease. J. Surg. Res. 2002, 102, 137-143
194. Crotty, S.; Johnston, R.J.; Schoenberger, S.P. Effectors and memories: Bcl-6 and Blimp-1 in T and B lymphocyte differentiation. Nat. Immunol. 2010, 11, 114-120
195. Eng, N.F.; Bhardwaj, N.; Mulligan, R.; Diaz-Mitoma, F. The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV review. Hum. Vaccin Immunother. 2013, 9, 1661-1672
196. FDA approves first adjuvanted vaccine for prevention of H5N1 avian influenza. Available online: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm376444.htm (accessed on 20 March 2014).
197. Tsai, T.F.; Crucitti, A.; Nacci, P.; Nicolay, U.; Della Cioppa, G.; Ferguson, J.; Clemens, R. Explorations of clinical trials and pharmacovigilance databases of MF59(R)-adjuvanted influenza vaccines for associated cases of narcolepsy. Scand. J. Infect. Dis. 2011, 43, 702-706
198. Singh, A.K.; Mahlios, J.; Mignot, E. Genetic association, seasonal infections and autoimmune basis of narcolepsy. J. Autoimmun. 2013, 43, 26-31
199. De la Herran-Arita, A.K.; Kornum, B.R.; Mahlios, J.; Jiang, W.; Lin, L.; Hou, T.; Macaubas, C.; Einen, M.; Plazzi, G.; Crowe, C.; et al. CD4+ T Cell Autoimmunity to Hypocretin/Orexin and Cross-Reactivity to a 2009 H1N1 Influenza A Epitope in Narcolepsy. Sci. Transl. Med. 2013, 5, doi:10.1126/scitranslmed.3007762
200. Arav-Boger, R.; Wojcik, G.L.; Duggal, P.; Ingersoll, R.G.; Beaty, T.; Pass, R.F.; Yolken, R.H. Polymorphisms in Toll-like receptor genes influence antibody responses to cytomegalovirus glycoprotein B vaccine. BMC Res. Notes. 2012, 5, doi:10.1186/1756-0500-5-140
201. Cho, P.; Gelinas, L.; Corbett, N.P.; Tebbutt, S.J.; Turvey, S.E.; Fortuno, E.S., 3rd; Kollmann, T.R. Association of common single-nucleotide polymorphisms in innate immune genes with differences in TLR-induced cytokine production in neonates. Genes Immun. 2013, 14, 199-211
202. Pothlichet, J.; Quintana-Murci, L. The genetics of innate immunity sensors and human disease. Int. Rev. Immunol. 2013, 32, 157-208
203. Clifford, H.D.; Hayden, C.M.; Khoo, S.K.; Naniche, D.; Mandomando, I.M.; Zhang, G.; Richmond, P.; Le Souef, P.N. Polymorphisms in key innate immune genes and their effects on measles vaccine responses and vaccine failure in children from Mozambique. Vaccine 2012, 30, 6180-6185
204. Ranatunga, D.; Hedrich, C.M.; Wang, F.; McVicar, D.W.; Nowak, N.; Joshi, T.; Feigenbaum, L.; Grant, L.R.; Stager, S.; Bream, J.H. A human IL10 BAC transgene reveals tissue-specific control of IL-10 expression and alters disease outcome. Proc. Natl. Acad. Sci. USA 2009, 106, 17123-17128
205. Lambert, N.D.; Ovsyannikova, I.G.; Pankratz, V.S.; Jacobson, R.M.; Poland, G.A. Understanding the immune response to seasonal influenza vaccination in older adults: A systems biology approach. Expert Rev. Vaccines 2012, 11, 985-994
206. Kollmann, T.R.; Levy, O.; Montgomery, R.R.; Goriely, S. Innate immune function by Toll-like receptors: Distinct responses in newborns and the elderly. Immunity 2012, 37, 771-783
207. Weber, D.J.; Rutala, W.A.; Samsa, G.P.; Santimaw, J.E.; Lemon, S.M. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. JAMA 1985, 254, 3187-3189
208. Eliakim, A.; Schwindt, C.; Zaldivar, F.; Casali, P.; Cooper, D.M. Reduced tetanus antibody titers in overweight children. Autoimmunity 2006, 39, 137-141
209. Mastelic, B.; Kamath, A.T.; Fontannaz, P.; Tougne, C.; Rochat, A.F.; Belnoue, E.; Combescure, C.; Auderset, F.; Lambert, P.H.; Tacchini-Cottier, F.; et al. Environmental and T cell-intrinsic factors limit the expansion of neonatal follicular T helper cells but may be circumvented by specific adjuvants. J. Immunol. 2012, 189, 5764-5772
210. McCarron, M.; Reen, D.J. Activated human neonatal CD8+ T cells are subject to immunomodulation by direct TLR2 or TLR5 stimulation. J. Immunol. 2009, 182, 55-62
211. Clemens, J.; Jodar, L. Introducing new vaccines into developing countries: Obstacles, opportunities and complexities. Nat. Med. 2005, 11, S12-S15
212. Bergmann-Leitner, E.S.; Duncan, E.H.; Mease, R.M.; Angov, E. Impact of pre-existing MSP1(42)-allele specific immunity on potency of an erythrocytic Plasmodium falciparum vaccine. Malar. J. 2012, 11, doi:10.1186/1475-2875-11-315
213. Halsey, N.A.; Boulos, R.; Mode, F.; Andre, J.; Bowman, L.; Yaeger, R.G.; Toureau, S.; Rohde, J.; Boulos, C. Response to measles vaccine in Haitian infants 6 to 12 months old. Influence of maternal antibodies, malnutrition, and concurrent illnesses. N. Engl. J. Med. 1985, 313, 544-549
214. Centers for Disease Control and Prevention. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly. Rep. 2010, 59, 626-629
215. Condie, R.M.; Zak, S.J.; Good, R.A. Effect of meningococcal endotoxin on the immune response. Proc. Soc. Exp. Biol. Med. 1955, 90, 355-360
216. McConkey, S.J.; Reece, W.H.; Moorthy, V.S.; Webster, D.; Dunachie, S.; Butcher, G.; Vuola, J.M.; Blanchard, T.J.; Gothard, P.; Watkins, K.; et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 2003, 9, 729-735
217. Koup, R.A.; Roederer, M.; Lamoreaux, L.; Fischer, J.; Novik, L.; Nason, M.C.; Larkin, B.D.; Enama, M.E.; Ledgerwood, J.E.; Bailer, R.T.; et al. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One 2010, 5, e9015
218. Leroux-Roels, I.; Roman, F.; Forgus, S.; Maes, C.; de Boever, F.; Drame, M.; Gillard, P.; van der Most, R.; van Mechelen, M.; Hanon, E.; et al. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study. Vaccine 2010, 28, 849-857
219. Zhu, Q.; Egelston, C.; Gagnon, S.; Sui, Y.; Belyakov, I.M.; Klinman, D.M.; Berzofsky, J.A. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J. Clin. Investig. 2010, 120, 607-616
220. Kwissa, M.; Amara, R.R.; Robinson, H.L.; Moss, B.; Alkan, S.; Jabbar, A.; Villinger, F.; Pulendran, B. Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus. J. Exp. Med. 2007, 204, 2733-2746
221. Rawlings, D.J.; Kaslow, D.C. Adjuvant-dependent immune response to malarial transmissionblocking vaccine candidate antigens. J. Exp. Med. 1992, 176, 1483-1487
222. Ireton, R.C.; Gale, M., Jr. RIG-I like receptors in antiviral immunity and therapeutic applications. Viruses 2011, 3, 906-919
223. Mercado-Lopez, X.; Cotter, C.R.; Kim, W.K.; Sun, Y.; Munoz, L.; Tapia, K.; Lopez, C.B. Highly immunostimulatory RNA derived from a Sendai virus defective viral genome. Vaccine 2013, 31, 5713-5721
224. Yount, J.S.; Kraus, T.A.; Horvath, C.M.; Moran, T.M.; Lopez, C.B. A novel role for viral-defective interfering particles in enhancing dendritic cell maturation. J. Immunol. 2006, 177, 4503-4513
225. Desel, C.; Werninghaus, K.; Ritter, M.; Jozefowski, K.; Wenzel, J.; Russkamp, N.; Schleicher, U.; Christensen, D.; Wirtz, S.; Kirschning, C.; et al. The Mincle-activating adjuvant TDB induces MyD88-dependent Th1 and Th17 responses through IL-1R signaling. PLoS One 2013, 8, e53531.